G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update

By Dr. Matthew Watson

-   New Drug Application (NDA) for trilaciclib in small cell lung cancer accepted for Priority Review with a PDUFA action date of February 15, 2021-   Announced CEO succession plan in evolution to commercial-stage company-   Management to host webcast and conference call today at 4:30 p.m. ET

Originally posted here:
G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update

Related Post


categoriaGlobal News Feed commentoComments Off on G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update | dataNovember 5th, 2020

About...

This author published 5432 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024